Recent Articles

May 4, 2016 4:13 pm
Ryan Bushey, Digital Editor
The Food and Drug Administration issued a warning on Tuesday that reports of compulsive binge-eating, shopping, gambling, and sex have been connected to the antipsychotic Abilify.
May 4, 2016 9:47 am
Ryan Bushey, Digital Editor
Pfizer could be joining the fray to compensate for its shuttered merger with Allergan. 
May 3, 2016 10:53 am
Ryan Bushey, Digital Editor
University of Oxford scientists have developed a gene therapy that has shown promise in treating choroideremia.
May 3, 2016 9:06 am
Ryan Bushey, Digital Editor
A small biotechnology company is attracting significant buyout interest from a slew of big drug makers. 
April 28, 2016 10:01 am
Jillian Godfrey Scaife, Principal, and Nick Simmons-Stern, Consultant, Trinity Partners
In recent years, there has been a resurgence in the number of Alzheimer’s disease (AD) clinical trials, led by major efforts from Biogen, Lilly, Genentech/Roche, and others. With the first of these novel AD therapies potentially coming to market as early as 2017/2018, there are a number of critical and as yet unanswered questions surrounding the economics and policy of AD diagnostic screening. 
April 26, 2016 2:00 pm
Adam Dion, MSc, Senior Industry Analyst, GlobalData
Many novel drugs are set to lose their patents by 2020, meaning South Korea’s generics market is expected to increase significantly.
April 26, 2016 3:23 pm
Dr. Premal Thaker M.D., Washington University School of Medicine; Dr. Charles Leath III, M.D., University of Alabama School of Medicine
In recent years, researchers have made considerable headway in efforts to improve both the pharmacokinetics and safety of therapies based on rIL-12 based on the use of more advanced delivery mechanisms.
April 26, 2016 12:28 pm
Ryan Bushey, Digital Editor
Vaccinations for three different influenza strains were given to an approximate 276 adults, over the age of 65.
April 25, 2016 4:42 pm
Ryan Bushey, Digital Editor
Google’s Calico, an institution with a mysterious mission to “cure death” could have competition from a new collaboration struck between Ascentage Pharma and Unity Biotechnology.
April 25, 2016 3:58 pm
Ryan Bushey, Digital Editor
Over the course of 12 weeks, patients were administered either Chantix or Zyban, a nicotine patch, or a placebo followed by an additional 12 weeks of follow-up.
Subscribe to Drug Discovery & Development